Bevacizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Bevacizumab is an anti-angiogenic drug that is used in the treatment of Metastatic Renal cell carcinoma, Metastatic breast cancer, Non-small cell lung cancer, and is also approved in the treatment Glioblastoma multiforme.[1]

References[change | change source]

  1. "Bevacizumab Gets Fast-Track Approval for Glioblastoma". www.medpagetoday.com. 6 May 2009.